WO2015088275A1 - Biodegradable medical adhesive or sealant composition - Google Patents
Biodegradable medical adhesive or sealant composition Download PDFInfo
- Publication number
- WO2015088275A1 WO2015088275A1 PCT/KR2014/012265 KR2014012265W WO2015088275A1 WO 2015088275 A1 WO2015088275 A1 WO 2015088275A1 KR 2014012265 W KR2014012265 W KR 2014012265W WO 2015088275 A1 WO2015088275 A1 WO 2015088275A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oxidized
- component
- composition
- adhesion
- hyaluronic acid
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 61
- 239000000853 adhesive Substances 0.000 title claims abstract description 40
- 230000001070 adhesive effect Effects 0.000 title claims abstract description 40
- 239000000565 sealant Substances 0.000 title claims abstract description 25
- 229920002683 Glycosaminoglycan Polymers 0.000 claims abstract description 35
- 229920000768 polyamine Polymers 0.000 claims abstract description 26
- 230000023597 hemostasis Effects 0.000 claims abstract description 14
- 238000011049 filling Methods 0.000 claims abstract description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 39
- 229920002674 hyaluronan Polymers 0.000 claims description 39
- 229960003160 hyaluronic acid Drugs 0.000 claims description 39
- 230000003647 oxidation Effects 0.000 claims description 22
- 238000007254 oxidation reaction Methods 0.000 claims description 22
- 125000003277 amino group Chemical group 0.000 claims description 17
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 15
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 15
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 15
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 15
- 230000000740 bleeding effect Effects 0.000 claims description 10
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 8
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 claims description 8
- 229920002873 Polyethylenimine Polymers 0.000 claims description 7
- 108010039918 Polylysine Proteins 0.000 claims description 6
- VHRGRCVQAFMJIZ-UHFFFAOYSA-N cadaverine Chemical compound NCCCCCN VHRGRCVQAFMJIZ-UHFFFAOYSA-N 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 229920000656 polylysine Polymers 0.000 claims description 6
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 claims description 6
- 102000009027 Albumins Human genes 0.000 claims description 5
- 108010088751 Albumins Proteins 0.000 claims description 5
- 229920002567 Chondroitin Polymers 0.000 claims description 5
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 claims description 5
- 229940063675 spermine Drugs 0.000 claims description 5
- 229920001661 Chitosan Polymers 0.000 claims description 4
- 102000007327 Protamines Human genes 0.000 claims description 4
- 108010007568 Protamines Proteins 0.000 claims description 4
- 229940048914 protamine Drugs 0.000 claims description 4
- 229940063673 spermidine Drugs 0.000 claims description 4
- 239000005700 Putrescine Substances 0.000 claims description 3
- 229920000045 Dermatan sulfate Polymers 0.000 claims description 2
- 229920002971 Heparan sulfate Polymers 0.000 claims description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 2
- 229920000669 heparin Polymers 0.000 claims description 2
- 229960002897 heparin Drugs 0.000 claims description 2
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 claims description 2
- 229920000288 Keratan sulfate Polymers 0.000 claims 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 claims 1
- 229940051593 dermatan sulfate Drugs 0.000 claims 1
- 238000001879 gelation Methods 0.000 abstract description 24
- 239000011248 coating agent Substances 0.000 abstract description 17
- 238000000576 coating method Methods 0.000 abstract description 17
- 230000002265 prevention Effects 0.000 abstract description 10
- 230000002439 hemostatic effect Effects 0.000 abstract description 5
- 230000001976 improved effect Effects 0.000 abstract description 4
- 238000006065 biodegradation reaction Methods 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
- 239000000499 gel Substances 0.000 description 17
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000012153 distilled water Substances 0.000 description 14
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- 208000032843 Hemorrhage Diseases 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 238000010521 absorption reaction Methods 0.000 description 9
- 206010052428 Wound Diseases 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 8
- 210000001015 abdomen Anatomy 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 229960003299 ketamine Drugs 0.000 description 5
- 210000003240 portal vein Anatomy 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000002271 resection Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- 210000000683 abdominal cavity Anatomy 0.000 description 4
- 239000013466 adhesive and sealant Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 238000000227 grinding Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229920001651 Cyanoacrylate Polymers 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 210000001156 gastric mucosa Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 3
- 229940012189 methyl orange Drugs 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 206010017788 Gastric haemorrhage Diseases 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229940050528 albumin Drugs 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 229940030225 antihemorrhagics Drugs 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical group OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000000227 bioadhesive Substances 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 239000010836 blood and blood product Substances 0.000 description 2
- 229940125691 blood product Drugs 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 239000002874 hemostatic agent Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000003232 mucoadhesive effect Effects 0.000 description 2
- 238000013059 nephrectomy Methods 0.000 description 2
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 2
- 210000002796 renal vein Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 229920001351 ε-poly-L-lysine Polymers 0.000 description 2
- FPJHWYCPAOPVIV-VOZMEZHOSA-N (2R,3S,4R,5R,6R)-6-[(2R,3R,4R,5R,6R)-5-acetamido-2-(hydroxymethyl)-6-methoxy-3-sulfooxyoxan-4-yl]oxy-4,5-dihydroxy-3-methoxyoxane-2-carboxylic acid Chemical compound CO[C@@H]1O[C@H](CO)[C@H](OS(O)(=O)=O)[C@H](O[C@@H]2O[C@H]([C@@H](OC)[C@H](O)[C@H]2O)C(O)=O)[C@H]1NC(C)=O FPJHWYCPAOPVIV-VOZMEZHOSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- CQVWXNBVRLKXPE-UHFFFAOYSA-N 2-octyl cyanoacrylate Chemical compound CCCCCCC(C)OC(=O)C(=C)C#N CQVWXNBVRLKXPE-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- RSVPPPHXAASNOL-UHFFFAOYSA-N Prodiamine Chemical compound CCCN(CCC)C1=C([N+]([O-])=O)C=C(C(F)(F)F)C(N)=C1[N+]([O-])=O RSVPPPHXAASNOL-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- -1 carboxylic acid compounds Chemical class 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- NLCKLZIHJQEMCU-UHFFFAOYSA-N cyano prop-2-enoate Chemical class C=CC(=O)OC#N NLCKLZIHJQEMCU-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000002767 hepatic artery Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- RPQUGMLCZLGZTG-UHFFFAOYSA-N octyl cyanoacrylate Chemical compound CCCCCCCCOC(=O)C(=C)C#N RPQUGMLCZLGZTG-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000002254 renal artery Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- 239000003106 tissue adhesive Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/08—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0031—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0042—Materials resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/009—Materials resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/042—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/145—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/148—Materials at least partially resorbable by the body
Definitions
- the present invention relates to a biodegradable medical adhesive or sealant composition
- a biodegradable medical adhesive or sealant composition comprising an oxidized glycosaminoglycan having a formyl group and a polyamine.
- Bioadhesives and sealants are used to seal or apply tissues during surgery, or to be used as anti-bleeding agents (hemostasis), body fluids and blood blockers. Bioadhesives and sealants require biocompatibility as they come into contact with the skin. It must be absent, biodegradable, and not interfere with the healing of living organisms.
- cyanoacrylates include cyanoacrylates, fibrin glues, gelatin glues, and polyurethanes. Closure Medi Cal of the United States commercialized a medical tissue adhesive of octylcyanoacrylate called Dermabond in 1997. It was approved by the US FDA in 1998 after it was approved by the European Community in August. However, cyanoacrylate-based adhesives may interfere with wound healing because the solids lack rigidity and rigidity, and are difficult to decompose in vivo, and thus are easily encapsulated and become foreign matters. there was. In addition, since fibrin glue has a considerably low adhesive force, the generated fibrin fish may drop from the tissue, and since the blood product is a blood product, there is a problem of a viral infection.
- Korean Patent Publication No. 10-2009-0083484 discloses a medical two-component adhesive comprising an aldehyde-ized textan powder and an ⁇ -poly—L-lysine powder prepared by mechanical grinding after lyophilization.
- LYDEX, Rydex is disclosed.
- the two-component adhesive is characterized in that it is a powdered medical adhesive, it takes a relatively long time to decompose the gel, there is a problem that does not obtain a satisfactory effect in the water absorption.
- new products with improved characteristics in terms of decomposition time, adhesion and water absorption There is an increasing demand for medical adhesives.
- numerous citations and patent documents are referenced and their citations are indicated. The disclosures of cited papers and patent documents are incorporated herein by reference in their entirety, and the level of the technical field to which the present invention belongs and the contents of the present invention are more clearly explained.
- the present inventors can perform sufficient adhesion, coating and hemostasis even in the part of the body where body fluid and blood are present, and can absorb a large amount of water, especially compared to other biodegradable polymers, and can decompose itself in the body. And research efforts were made to develop sealants. As a result, the present invention is confirmed that the use of a formyl group and oxidized glycosaminoglycan and polyamine together can effectively bond, layer, apply, prevent adhesion, wound coating and hemostasis of living tissues. It was completed.
- an object of the present invention is to provide a medical adhesive or sealant (or a medical adhesive or sealant composition).
- Another object of the present invention is to provide a method for adhesion, layer deposition, application, adhesion prevention, wound coating or hemostasis of living tissue.
- the invention provides a biodegradable medical adhesive or sealant (or medical adhesive or sealant composition) comprising:
- a first component comprising an oxidized glycosaminoglycan in which a formyl group is introduced and oxidized
- a second component comprising a polyamine having two or more amino groups, wherein the pH in the aqueous solution state of the second component is 8.5 to 11.0.
- the invention provides a biodegradable medical adhesive or sealant (or medical adhesive or sealant composition) comprising:
- a second component comprising a polyamine having two or more amino groups, the pH in the aqueous solution state of the second component is 8.5 to 11.0,
- the present invention is the step of applying the biodegradable medical adhesive or sealant (or medical adhesive or sealant composition) to a biological tissue that requires adhesion, layering, application, adhesion prevention, wound coating or hemostasis It provides a method of adhesion, layer deposition, coating, adhesion prevention, wound coating or hemostasis of a biological tissue comprising a.
- the present inventors can perform sufficient adhesion, coating and hemostasis even in the part of the body where body fluids and blood are present, and in particular, can absorb a large amount of water compared to other biodegradable polymers and can decompose itself in the body. And research efforts were made to develop sealants.
- the composition of the present invention showed an improved effect on gel formation time, adhesion and water absorption than the conventional medical two-component adhesive (LYDEX) (see Tables 5 to 7), In addition, it showed a better effect than the conventional hemostatic agent (Ar i sta TM AH) (see Fig. 12).
- the composition of the present invention comprises oxidized glycosaminoglycan as the first component.
- oxidized glycosaminoglycan means that a formyl group (-CH0) is introduced and oxidized to glycosaminoglycan.
- the glycosamino glycan is distinguished from glucan, which is a 0-glycoside bond of a monosaccharide, in that it is a polysaccharide having a repeating structure of a disaccharide including nucleosamine.
- Introduction of such a formyl group can be performed by a periodic acid oxidation method.
- oxidized glycosaminoglyco introduced with the appropriate number (eg, 0.01 to 0.95) formyl groups per anhydrous glucose unit (sugar moiety) by oxidation with glycosaminoglycanol periodic acid or periodicate You can get a space.
- Oxidation degree of this glycosaminoglycan Calculated according to, having a value from 10 to 99.5%. Oxidized glycosaminoglycans having such a degree of oxidation, when used in combination with the second component, can quickly absorb the blood and body fluids in the body and gelate quickly.
- the oxidation degree of the oxidized glycosaminoglycan is
- the oxidation degree of the oxidized hyaluronic acid may be 10-20%.
- Oxidation degree measurement of the glycosaminoglycan can be carried out by NaOH scoring method. For example, 17.5 g of hydroxylamine hydrochloride and 0.05% methyl orange 6 are mixed in 994 distilled water to form a solution of 0.25 ⁇ / ⁇ hydroxylamine hydrochloride, titrated ⁇ to 4, and then Dissolve 0.1 g of minoglycan in 25 ⁇ of the above solution, titrate it again to pH 4 with 0.1 ⁇ / i sodium hydroxide, , , ⁇ , , ,
- the oxidized glycosaminoglycan has 0.01 to 0.95 formyl groups per anhydrous glucose unit (sugar residues).
- the oxidized glycosaminoglycan is composed of oxidized hyaluronic acid, oxidized chondroitin sulfate, oxidized chondroitin, dermatan sulphate, oxidized heparan sulphate, heparin oxidized and keratan oxidized. Is selected from.
- the gelling ability of the adhesive / sealant composition by using a glycosaminoglycan having a specific molecular weight, the gelling ability of the adhesive / sealant composition, the gelation state retention time, the elasticity of the gel, and the like can be appropriately controlled.
- the glycosaminoglycan used to obtain the oxidized glycosaminoglycan has a molecular weight of 1,000 to 5 million.
- the glycosaminoglycan used to obtain the oxidized glycosaminoglycan is 10,000 to 4 million, 50,000 to 350, 100,000 to 350, 100,000 to 3 million, 100,000 to 2.5 million, 100,000 To 2 million, or 100,000 to 1.6 million molecular weight.
- the first component is 100,000 to
- Oxidized hyaluronic acid with a molecular weight of 2 million is included. According to one specific example, the molecular weight of the oxidized hyaluronic acid is 100,000 to 1.6 million.
- the first component includes two or more kinds of oxidized glycosaminoglycans.
- the weight ratio of these oxidized glycosaminoglycans is 1: 0.5-5. According to one specific example, the weight ratio of the oxidized glycosaminoglycan is 1: 0.5-4, and in another specific example 1: 0.5.
- the two or more kinds of oxidation Glycosaminoglycans are oxidized hyaluronic acid and oxidized chondroitin sulfate.
- the weight ratio of the hyaluronic acid oxide and chondroitin oxide is 1: 0.5-5, 1: 0.5-4, 1: 0.5-3.5, 1: 0.5-3, 1: 0.5-2.5, 1: 0.5-2, 1: 0.5 -1.5 or 1: 0.8-
- the oxidation degree of the oxidized hyaluronic acid is 10-.
- the oxidation degree of the oxidized hyaluronic acid is 12-40%, in another specific example 12-383 ⁇ 4>, and in another specific example 13-3.
- the oxidation degree of the oxidized chondroitin sulfate is 10-55%.
- the oxidation degree of the chondroitin sulfate is 10-50%, in another specific example 10-45%, in another specific example 10-40%, in another specific example 10 -35%.
- the first component is in powder, liquid or solid (eg pellet form).
- the powdery first component may be obtained by drying (eg, spray drying, lyophilization, etc.) of an oxidized glycosaminoglycan-containing solution followed by grinding (eg, mechanical grinding).
- composition of the present invention further comprises a second component comprising a polyamine having two or more amino groups in addition to the first component as the active component.
- the second component exhibits a pH of 8.5-11.0 in aqueous solution. As confirmed in the following examples, when the pH in the aqueous solution state of the second component is 8.5-11.0, gelation may be performed within a few seconds (see FIG. 7).
- the second component is 9.0- in an aqueous solution state.
- the pleamine may further have a secondary and / or tertiary amino group.
- the second component comprising the polyamine is in powder, liquid or solid (eg, pellets).
- the powdery second component can be obtained by drying and grinding the polyamine-comprising solution.
- the polyamine-containing solution may further include a pH adjusting agent so that the pH range in the aqueous solution state of the second component is 8.5-11.0.
- the pH regulator include monovalent or polyvalent carboxylic acid compounds such as acetic acid, citric acid, succinic acid, glutaric acid, malic acid, fumaric acid and maleic acid, or anhydrides thereof.
- the polyamine is polylysine, chitosan, albumin, putrescine (putrescine), cadaverine (cadaver ine), spermidine, spermine (spermine), protamine and PEI (Polyethylenimine) is selected from the group consisting of.
- the polyamine has a molecular weight of 100 or more.
- the molecular weight of the polyamine may be 1,000 to 200,000.
- the polyamine is poly-L-lysine.
- the poly-L-lysine may be ⁇ -poly-L-lysine produced using microorganisms (eg, Straptomyces abulus) or enzymes.
- the second component may further comprise a ⁇ regulator in addition to the polyamine.
- the composition of the present invention may further comprise a drug.
- the drug may be included in the second component.
- the drug is
- It may have one or more amine groups, and examples of such drugs include anthracycline-based drugs, gemcitabine, vancomycin, polymycin, methotrexate, protein drugs and peptide drugs.
- anthracycline-based drugs gemcitabine, vancomycin, polymycin, methotrexate, protein drugs and peptide drugs.
- the amine group of the drug may also act as the formyl group of the first component, and the three components may form a gel together.
- the composition of the present invention may be formulated in various forms, for example, a first component which is in powder form, liquid form or solid form (for example, pellet form), and is in powder form, liquid form or solid form. Combinations of second components.
- the composition of the present invention comprises the first component and the second component in a weight ratio of 0.5-10: 1.
- the first component and the second component are included in a weight ratio of 0.5-8: 1, in another specific example, a weight ratio of 0.5-6: 1, and in another specific example, 0.5-4: 1 Weight ratio, in another specific example a weight ratio of 0.5-3: 1, in another specific example, a weight ratio of 0.5-2: 1, in another specific example, a weight ratio of 0.5-1.5: 1, and in another specific example, 0.8-1.5: Weight ratio of 1, and in another specific example, weight ratio of 0.8-1.2: 1.
- the present invention by controlling the ratio of the formyl group of the first component and the amino group of the second component it is possible to control the gel formation time, the decomposition time of the resulting gel and the like.
- the molar ratio of formyl group / amino group is 0.1-500.
- the molar ratio of formyl group / amino group is 1-400, 1_350 in another specific example, 1-300 in another specific example, and another specific example. In the example, 10–300.
- the first component and the second component may be applied to the adherend (skin surface inside and outside the living body) simultaneously or sequentially for a medical effect (medical use).
- a medical effect medical use
- saline or distilled water may be sprayed in order to gel the first and second components.
- the medical use is selected from the group consisting of adhesion, layer deposition, application, adhesion prevention, wound coating and hemostasis of biological tissue.
- the composition of the present invention provides the first component and the second component in a form contained in the same container, or in a form separately contained in a separate container.
- the present invention provides a biodegradable medical adhesive or sealant composition comprising an oxidized glycosaminoglycan and a polyamine.
- composition of the present invention shows an improved effect in biodegradable coating properties, gelation time, hemostatic capacity, adhesion and water absorption.
- composition of the present invention can be utilized for various medical applications in which medical adhesives or sealants can be used, such as adhesion, layering, coating, adhesion prevention, wound coating, leakage prevention, and hemostasis of biological tissues.
- Figure 1 shows the results of the analysis of oxidized hyaluronic acid using an FT-IR spectrometer.
- FIG. 3 is a photograph showing the results of gelation evaluation of the first and second component mixtures mixed in different weight ratios.
- Figure 4 is a photograph showing a comparison of the gelation time of the adhesive and sealant composition of the present invention and the conventional adhesive composition (Lydex).
- 5 is a graph showing the adhesive strength of the adhesive and sealant composition of the present invention and the conventional adhesive composition (Litex).
- Figure 6 is a photograph showing the results (mucoadhesion and hemostatic capacity) after applying the adhesive and sealant composition of the present invention, or a conventional adhesive composition (Lydex) to the bleeding site after gastric mucosal resection.
- Figure 7 is a photograph showing the gelation state and gelation time of the oxidized glycosaminoglycans and polyamine mixtures and the gelation according to pH.
- FIGS. 8 to 11 show the results of comparative experiments between the adhesive and sealant composition of the present invention and the conventional hemostatic agent (Ar i sta TM AH) performed on the mesenchymal resection model, nephrectomy model, gastric mucosal resection model, and blood vessel application model.
- . 12 is a graph quantitatively showing the results of FIGS. 8 to 11.
- the oxidized hyaluronic acid obtained here was lyophilized for at least 4 days, then pulverized and passed through a 500 ⁇ sized mesh to obtain an oxidized hyaluronic acid having a diameter of about 500 im or less.
- Oxidized hyaluronic acid was analyzed using an FT-IR spectrometer (Cary 640, Agilent Technologies, USA), and the substituent was confirmed at 4000-400 cm ' Hresolution 4 cm- 1 (FIG. 1).
- chitosan, protamine, PEI, polylysine, spermine, spermidine, and albumin were used as second components, and pH adjusters (acid, acid, base, base salt, etc.) from 5% by weight or more of aqueous polyamine solution After adjusting the pH to 8.5, 9.0, 9.5 and 10 using the same as in the case of the oxidized hyaluronic acid / oxidized chondroitin sulfate, the powder obtained after freeze drying was used.
- Example 1 The first and second components obtained in Example 1 were mixed in different weight ratios (1: 1, 2: 1,
- LYDEX showed an average adhesive strength of 53.6 gf even though a small amount (500 water was applied) of LYDEX compared to the oxidized hyaluronic acid mixture. Measured at 65.9 and 67.5 gf (FIG. 5 and Table 6).
- a mucosectomy-induced gastric bleeding model in rabbits was constructed as follows.
- the rabbits were fasted for 24 hours prior to surgery and anesthetized by intramuscular injection of a combination of ketamine (4.2 mg / kg) and silazine (11.7 mg / kg).
- the upper abdomen of the rabbit was incised to expose the stomach and incision about 5-7 cm along the great curvature of the stomach.
- Isotonic saline 200 was injected into the submucosal layer of the stomach, and the swollen gastric mucosa was excised using surgical scissors. The diameter of the excised site was about 7-10 mm 3.
- the degree of substitution (oxidation degree) of hyaluronic acid and chondroitin sulfate was confirmed by NaOH titration. Specifically, 17.5 g of hydroxylamine hydrochloride and 0.05% methyl orange 6 11 were mixed in 994 ⁇ distilled water to make a 0.25 1 ⁇ 1 / £ hydroxylamine hydrochloride solution and the pH was titrated to 4. 0.1 g of hyaluronic acid black silver chondroitin sulfate was dissolved in 25 m of the above solution and titrated again to pH 4 with 0.1 ⁇ / ⁇ sodium hydroxide. Substitution degree (%) was calculated using the following formula, and the results were as shown in Tables 8 and 9. Equation 3
- chitosan, protamine PEI, polylysine, spermine, spermidine, and albumin were selected as the second component, and as a second component, to find out whether the gelation was performed according to pH.
- aqueous solution after adjusting the pH to various ranges (5.5-6.4, 6.5-7.4, 7.5-8.4, 8.5-9.4, 9.5-10.4, 10.5-11), the same as in the case of the oxidized hyaluronic acid / oxidized chondroitin sulfate
- the powder obtained after freeze drying was used. Oxidized hyaluronic acid / oxidized chondroitin sulfate of the first component and polyamine were mixed.
- Anesthesia was injected by injection of a ketamine and lump mixture into the abdominal cavity of male SD rats weighing 200-300 g, and the central upper abdomen was incised approximately 3-4 cm in length or width.
- the mesenchyme was exposed using a wet gauze into the incision of the incised abdomen, and the portal vein and hepatic artery were ligated with a vascular clip. About 1 cm away from the edge of the mesenchyme was excised with surgical scissors and 50-100 mg of UI-SAH was applied.
- Ar i sta TM AH (Medafor Inc., USA) was applied. After application, the ligated clip was removed after ligating, and the amount of bleeding was measured using sterile gauze.
- Anesthesia was injected by injection of a ketamine and lump mixture into the abdominal cavity of male SD rats weighing 200-300 g, and the central upper abdomen was incised about 5-6 cm vertically or horizontally.
- the portal vein was exposed after moving other organs to the left axis through the incised abdominal gap.
- Two sites above and below the portal vein were ligated with a vascular clip.
- UI-SAH 50-100 mg was applied after puncturing the portal vein using an 18 gauge needle.
- Ar i sta TM AH (Medafor Inc., USA) was applied. After application, the ligated clip was removed after removing the ligated clip, and the bleeding amount was measured using sterile gauze.
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Surgery (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Dispersion Chemistry (AREA)
- Vascular Medicine (AREA)
- Medicinal Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2014360958A AU2014360958B2 (en) | 2013-12-13 | 2014-12-12 | Biodegradable medical adhesive or sealant composition |
RU2016128376A RU2657836C1 (en) | 2013-12-13 | 2014-12-12 | Biodegradable medical adhesive or sealant composition |
CN201480067775.9A CN106061518B (en) | 2013-12-13 | 2014-12-12 | Biodegradable medical adhesive or sealant composition |
CA2933271A CA2933271C (en) | 2013-12-13 | 2014-12-12 | Biodegradable medical adhesive or sealant composition |
US15/102,406 US10105465B2 (en) | 2013-12-13 | 2014-12-12 | Biodegradable medical adhesive or sealant composition |
JP2016538741A JP6207745B2 (en) | 2013-12-13 | 2014-12-12 | Biodegradable medical adhesive or sealant composition |
EP14870365.5A EP3081236B1 (en) | 2013-12-13 | 2014-12-12 | Biodegradable medical adhesive or sealant composition |
MX2016007688A MX366143B (en) | 2013-12-13 | 2014-12-12 | Biodegradable medical adhesive or sealant composition. |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20130155722 | 2013-12-13 | ||
KR10-2013-0155722 | 2013-12-13 | ||
KR10-2014-0089173 | 2014-07-15 | ||
KR1020140089173A KR101664444B1 (en) | 2013-12-13 | 2014-07-15 | Biodegradable medical adhesive or sealant compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015088275A1 true WO2015088275A1 (en) | 2015-06-18 |
Family
ID=53371497
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2014/012265 WO2015088275A1 (en) | 2013-12-13 | 2014-12-12 | Biodegradable medical adhesive or sealant composition |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2015088275A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112451735A (en) * | 2019-09-09 | 2021-03-09 | 天津大学 | Epsilon-polylysine-based mussel-like coordination adhesive and preparation method thereof |
CN116687959A (en) * | 2022-05-18 | 2023-09-05 | 朱小丰 | Chondroitin sulfate biological polyamine complex, and preparation method and application thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050045113A (en) * | 2003-11-10 | 2005-05-17 | 주식회사 바이오레인 | Anti-adhesion agent with gas bubble |
US20050238702A1 (en) * | 2002-04-23 | 2005-10-27 | Netech, Inc | Medical composition containing photocrosslinkable chitosan derivative |
JP2006347883A (en) * | 2003-09-08 | 2006-12-28 | Neetec:Kk | Composition for medical treatment comprising sugar chain-containing chitosan derivative and glycosaminoglycan |
KR20070100230A (en) * | 2007-04-05 | 2007-10-10 | 베이코 테크 리미티드 | Hyaluronic acid coated bone implant device |
KR20090083484A (en) | 2006-11-30 | 2009-08-03 | 가부시끼가이샤 비엠지 | Self-degradable adhesive for medical use of two-component reactant system comprising powder-liquid or powder-powder |
KR20120089506A (en) * | 2010-12-10 | 2012-08-13 | 포항공과대학교 산학협력단 | Hyaluronic acid-protein conjugate, and preparation method thereof |
-
2014
- 2014-12-12 WO PCT/KR2014/012265 patent/WO2015088275A1/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050238702A1 (en) * | 2002-04-23 | 2005-10-27 | Netech, Inc | Medical composition containing photocrosslinkable chitosan derivative |
JP2006347883A (en) * | 2003-09-08 | 2006-12-28 | Neetec:Kk | Composition for medical treatment comprising sugar chain-containing chitosan derivative and glycosaminoglycan |
KR20050045113A (en) * | 2003-11-10 | 2005-05-17 | 주식회사 바이오레인 | Anti-adhesion agent with gas bubble |
KR20090083484A (en) | 2006-11-30 | 2009-08-03 | 가부시끼가이샤 비엠지 | Self-degradable adhesive for medical use of two-component reactant system comprising powder-liquid or powder-powder |
KR20070100230A (en) * | 2007-04-05 | 2007-10-10 | 베이코 테크 리미티드 | Hyaluronic acid coated bone implant device |
KR20120089506A (en) * | 2010-12-10 | 2012-08-13 | 포항공과대학교 산학협력단 | Hyaluronic acid-protein conjugate, and preparation method thereof |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112451735A (en) * | 2019-09-09 | 2021-03-09 | 天津大学 | Epsilon-polylysine-based mussel-like coordination adhesive and preparation method thereof |
CN116687959A (en) * | 2022-05-18 | 2023-09-05 | 朱小丰 | Chondroitin sulfate biological polyamine complex, and preparation method and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101664444B1 (en) | Biodegradable medical adhesive or sealant compositions | |
Sanandiya et al. | Tunichrome-inspired pyrogallol functionalized chitosan for tissue adhesion and hemostasis | |
JP4092512B2 (en) | Self-degradable medical two-component reactive adhesive and medical resin | |
CN101583383B (en) | Self-degradable adhesive for medical use of two-component reactant system comprising powder-liquid or powder-powder | |
WO2019137414A1 (en) | Method for treating active bleeding using biocompatible hemostatic and sealant compositions | |
EP3815697B1 (en) | Two-component hemostatic composition and method of manufacturing same | |
EP1796746A2 (en) | Polysaccharide-based polymer tissue adhesive for medical use | |
CA2849288A1 (en) | Hydrogel comprising catechol group-coupled chitosan or polyamine and poloxamer comprising thiol group coupled to end thereof, preparation method thereof, and hemostat using same | |
US20190083676A1 (en) | Composite bioadhesive sealant | |
EP2214730A2 (en) | Dextran-based polymer tissue adhesive for medical use | |
EP2416811A1 (en) | Hydrogel tissue adhesive having reduced degradation time | |
JP4267106B2 (en) | Anti-adhesion material | |
WO2018079538A1 (en) | Hemostatic material | |
WO2004081055A1 (en) | Crosslinkable polysaccharide derivative, process for producing the same, crosslinkable polysaccharide composition and medical treatment material | |
WO2015088275A1 (en) | Biodegradable medical adhesive or sealant composition | |
Choi et al. | Immediately activating hemostatic cellulose sealants for uncontrolled hemorrhage |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14870365 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15102406 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2933271 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2016538741 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2016/007688 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2014870365 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014870365 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2016128376 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2014360958 Country of ref document: AU Date of ref document: 20141212 Kind code of ref document: A |